CareLit Fachartikel

Multityrosinkinase inhibition by sorafenib increases necrosis size after radiofrequency ablation in rat liver but activates compensatory growth signaling

J Mertens, I Martin, P Frei, AH Mahnken, P Bruners, B Müllhaupt, A Geier · Zeitschrift für Gastroenterologie · 2009 · Heft 09

Dokument
1043225
CareLit-ID
Jahr
2009
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Zeitschrift für Gastroenterologie
Autor:innen
J Mertens, I Martin, P Frei, AH Mahnken, P Bruners, B Müllhaupt, A Geier
Ausgabe
Heft 09 / 2009
Seiten
–
Erschienen: 2009-09-28 00:00:00
ISSN
0044-2771
DOI
10.1055/s-0029-1241635

Zusammenfassung

Aims: The most widely employed local ablative treatment for unresectable HCC is radiofrequency ablation (RFA). The multityrosinkinase inhibitor sorafenib has shown survival benefits in pts at advanced stages and is currently under investigation for adjuvant treatment after HCC resection/ablation in human trials. Of potential concern, sorafenib may reduce liver regeneration after tissue ablation. Furthermore, antiangiogenic therapy could increase the likelihood of tumour spread. Aim: To evaluate effects of sorafenib treatment following RFA in rats on necrosis size and growth signaling pathways. Methods: Male SD r…

Schlagworte

After Cytokines Cyclin E Cyclins Blood Tumor Zeitschrift für Gastroenterologie